Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARK S KIPNES

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1376501965
CMS profile
16338
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$3,903.12

223 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,903.12 223

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 223 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARK S KIPNES

NPI 1376501965 · CMS profile ID 16338

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 223 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1376501965?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARK S KIPNES, NPI 1376501965, CMS profile ID 16338. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 223 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1376501965?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MARK S KIPNES, NPI 1376501965, CMS profile ID 16338. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 223 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1376501965?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MARK S KIPNES, NPI 1376501965, CMS profile ID 16338, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 223 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1376501965?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

223 matching records · $3,903.12 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 223 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 223.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Becton, Dickinson and Company $18.1007/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836114583 CMS
Amarin Pharma Inc. $17.5507/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815056075 CMS
Antares Pharma, Inc. $4.2607/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827509113 CMS
Antares Pharma, Inc. $2.2607/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827511543 CMS
Xeris Pharmaceuticals, Inc. $20.9707/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837430091 CMS
Amarin Pharma Inc. $6.4407/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815056071 CMS
Amgen Inc. $13.4107/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825588803 CMS
Lilly USA, LLC $14.5406/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818637765 CMS
DEXCOM, INC. $19.3006/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845284547 CMS
Novo Nordisk Inc $24.2506/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810711719 CMS
Novo Nordisk Inc $4.3506/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811529183 CMS
AstraZeneca Pharmaceuticals LP $21.2106/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829438209 CMS
Antares Pharma, Inc. $7.0906/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827511547 CMS
AbbVie Inc. $14.9906/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795111307 CMS
Novo Nordisk Inc $11.7806/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811529177 CMS
Amarin Pharma Inc. $17.7706/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815341357 CMS
Amgen Inc. $24.4706/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825588827 CMS
AstraZeneca Pharmaceuticals LP $17.9806/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829657963 CMS
Corcept Therapeutics $19.7706/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837537799 CMS
Novo Nordisk Inc $20.4706/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810711715 CMS
SANOFI-AVENTIS U.S. LLC $17.6306/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843407605 CMS
Xeris Pharmaceuticals, Inc. $23.6506/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837430087 CMS
AstraZeneca Pharmaceuticals LP $110.0106/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830108313 CMS
Antares Pharma, Inc. $8.0306/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827506755 CMS
Abbott Laboratories $20.0106/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815529495 CMS
DEXCOM, INC. $14.8206/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845284545 CMS
Medtronic, Inc. $17.8906/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815778755 CMS
Zealand Pharma US, Inc. $14.5006/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 800227823 CMS
Esperion Therapeutics, Inc. $20.3306/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838329563 CMS
AstraZeneca Pharmaceuticals LP $14.1305/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829911183 CMS
AbbVie Inc. $24.9605/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795111303 CMS
AbbVie Inc. $14.9505/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795111299 CMS
Amarin Pharma Inc. $18.1805/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815249239 CMS
MannKind Corporation $31.4005/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821063587 CMS
Novo Nordisk Inc $18.8605/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811529173 CMS
Antares Pharma, Inc. $8.0305/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827509103 CMS
Esperion Therapeutics, Inc. $17.2405/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838329559 CMS
AstraZeneca Pharmaceuticals LP $17.6305/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829803547 CMS
Abbott Laboratories $19.4405/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815635475 CMS
Amgen Inc. $12.6805/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825588799 CMS
Antares Pharma, Inc. $9.6805/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827509099 CMS
Zealand Pharma US, Inc. $18.4305/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 800227821 CMS
Radius Health, Inc. $23.8005/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830731889 CMS
Novo Nordisk Inc $24.0505/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811237469 CMS
Xeris Pharmaceuticals, Inc. $23.8705/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837430081 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.8204/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763340160 CMS
Esperion Therapeutics, Inc. $10.7204/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838329555 CMS
Novo Nordisk Inc $9.4604/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811744253 CMS
Lilly USA, LLC $12.5104/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818645665 CMS
Antares Pharma, Inc. $8.4504/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827510149 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,133.28 244
PY2020 $4,522.67 227
PY2021 $3,903.12 223
PY2022 $3,603.11 213
PY2023 $5,762.80 170
PY2024 $2,621.23 87
PY2025 $2,970.05 78

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,656.03 8
PY2025 Principal investigator $1,171,555.95 249
PY2024 Recipient $3,113.38 12
PY2024 Principal investigator $1,137,983.25 200
PY2023 Recipient $164.91 1
PY2023 Principal investigator $1,514,072.07 219
PY2022 Principal investigator $1,386,339.21 187
PY2021 Principal investigator $2,414,228.79 186
PY2020 Recipient $6,689.92 1
PY2020 Principal investigator $1,435,762.62 172
PY2019 Principal investigator $1,191,568.80 86

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

257 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,709.00 12/31/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC PA
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202533155
Principal investigator 1 Abbott Laboratories $310.00 12/18/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162820
Principal investigator 1 Abbott Laboratories $144.00 12/18/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162822
Principal investigator 1 Abbott Laboratories $148.00 12/18/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162824
Principal investigator 1 Abbott Laboratories $158.00 12/18/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162826
Principal investigator 1 Abbott Laboratories $148.00 12/18/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162828
Principal investigator 1 Boehringer Ingelheim International GmbH $255.50 12/17/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683657
Principal investigator 1 Boehringer Ingelheim International GmbH $12.18 12/17/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683659
Principal investigator 1 Boehringer Ingelheim International GmbH $16.56 12/17/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683661
Principal investigator 1 Abbott Laboratories $3.10 12/16/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162816
Principal investigator 1 Abbott Laboratories $366.00 12/16/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162818
Principal investigator 1 Abbott Laboratories $91,161.00 12/12/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248160388
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,530.60 12/10/2025 Non-covered Recipient Entity
Diabetes & Glandular Disease Clinic, P.A
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220809953
Principal investigator 1 Abbott Laboratories $13.95 12/08/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162814
Principal investigator 1 ABBVIE INC. $1,665.90 12/05/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202529424
Principal investigator 1 Ionis Pharmaceuticals, Inc. $900.00 12/03/2025 Non-covered Recipient Entity
DIABETES & GLANDULAR DISEASE CLINIC PA
IS354CS15 No dispute reported 06/30/2026 1246791029
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683606
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683608
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683655
Principal investigator 1 Abbott Laboratories $496.00 11/19/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162704
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 11/19/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683614
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 11/19/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683616
Principal investigator 1 Boehringer Ingelheim International GmbH $88.44 11/19/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683618
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 11/19/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683620
Principal investigator 1 Boehringer Ingelheim International GmbH $16.56 11/19/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683622
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $623.70 11/13/2025 Non-covered Recipient Entity
Diabetes & Glandular Disease Clinic, P.A
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220809951
Principal investigator 1 Abbott Laboratories $915.00 11/11/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162580
Principal investigator 1 Abbott Laboratories $27.90 11/11/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162582
Principal investigator 1 Abbott Laboratories $17,425.81 11/07/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248160384
Principal investigator 1 ABBVIE INC. $32,223.15 11/05/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202523061
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683604
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683651
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683653
Principal investigator 1 Ionis Pharmaceuticals, Inc. $3,742.20 10/31/2025 Non-covered Recipient Entity
DIABETES & GLANDULAR DISEASE CLINIC PA
IS354CS15 No dispute reported 06/30/2026 1246789864
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 10/27/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683610
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 10/27/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683612
Principal investigator 1 Abbott Laboratories $17.40 10/15/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162376
Principal investigator 1 Abbott Laboratories $13.95 10/15/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162378
Principal investigator 1 Abbott Laboratories $14,999.70 10/15/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162380
Principal investigator 1 Insulet Corporation $33,885.71 10/15/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLIN
Safety and Efficacy of the Omnipod 5 SmartAdjust 2.0 System Compared to the Omnipod 5 System in Individuals with Type 1 or Type 2 Diabetes No dispute reported 06/30/2026 1206961929
Principal investigator 1 Abbott Laboratories $3.10 10/10/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162242
Principal investigator 1 Abbott Laboratories $164.00 10/10/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162244
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,343.70 10/10/2025 Non-covered Recipient Entity
Diabetes & Glandular Disease Clinic, P.A
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220809927
Principal investigator 1 ABBVIE INC. $19,696.50 10/09/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202516049
Principal investigator 1 Abbott Laboratories $164.00 10/08/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162236
Principal investigator 1 Abbott Laboratories $124.00 10/08/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162238
Principal investigator 1 Abbott Laboratories $1.55 10/08/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248162240
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683602
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683647
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683649
Principal investigator 1 Abbott Laboratories $57,455.00 09/30/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248137974
Principal investigator 1 Abbott Laboratories $26.25 09/26/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157564
Principal investigator 1 Abbott Laboratories $9.00 09/26/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157566
Principal investigator 1 Abbott Laboratories $13.00 09/26/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157568
Principal investigator 1 Abbott Laboratories $58.50 09/26/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157570
Principal investigator 1 Abbott Laboratories $211.20 09/26/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157572
Principal investigator 1 Abbott Laboratories $71.40 09/26/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157574
Principal investigator 1 Abbott Laboratories $36.00 09/26/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157576
Principal investigator 1 Abbott Laboratories $555.00 09/26/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157578
Principal investigator 1 Abbott Laboratories $2,723.66 09/26/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157580
Principal investigator 1 Abbott Laboratories $14,970.00 09/26/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157582
Principal investigator 1 Abbott Laboratories $320.85 09/26/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157584
Principal investigator 1 Abbott Laboratories $171.30 09/26/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157586
Principal investigator 1 Abbott Laboratories $17.40 09/26/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157588
Principal investigator 1 Abbott Laboratories $18.99 09/26/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157590
Principal investigator 1 Abbott Laboratories $82.50 09/26/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157592
Principal investigator 1 Abbott Laboratories $53.10 09/26/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157594
Principal investigator 1 Abbott Laboratories $610.00 09/26/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157596
Principal investigator 1 Abbott Laboratories $372.00 09/26/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157598
Principal investigator 1 Abbott Laboratories $38.00 09/26/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157602
Principal investigator 1 Abbott Laboratories $222.00 09/26/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157604
Principal investigator 1 Abbott Laboratories $222.00 09/26/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157606
Principal investigator 1 Abbott Laboratories $372.00 09/26/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157608
Principal investigator 1 Abbott Laboratories $222.00 09/26/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157610
Principal investigator 1 Abbott Laboratories $222.00 09/26/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157612
Principal investigator 1 Abbott Laboratories $210.00 09/26/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157614
Principal investigator 1 Abbott Laboratories $9.30 09/26/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157616
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 09/24/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683600
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 09/24/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683645
Principal investigator 1 Abbott Laboratories $1,459.37 09/23/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248137968
Principal investigator 1 Ionis Pharmaceuticals, Inc. $2,182.50 09/23/2025 Non-covered Recipient Entity
DIABETES & GLANDULAR DISEASE CLINIC PA
IS354CS15 No dispute reported 06/30/2026 1246787591
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/22/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220801050
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/22/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220801052
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/22/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220801054
Principal investigator 1 ABBVIE INC. $6,984.75 09/18/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202511416
Principal investigator 1 ABBVIE INC. $26,397.90 09/04/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202509114
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,343.70 09/03/2025 Non-covered Recipient Entity
Diabetes & Glandular Disease Clinic, P.A
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220809929
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,347.20 09/03/2025 Non-covered Recipient Entity
Diabetes & Glandular Disease Clinic, P.A
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220809949
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683580
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683582
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683639
Principal investigator 1 Ionis Pharmaceuticals, Inc. $4,402.80 08/29/2025 Non-covered Recipient Entity
DIABETES & GLANDULAR DISEASE CLINIC PA
IS354CS15 No dispute reported 06/30/2026 1246786977
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 08/26/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683592
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 08/26/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683594
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 08/26/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683596
Principal investigator 1 Boehringer Ingelheim International GmbH $8.28 08/26/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683598
Principal investigator 1 Boehringer Ingelheim International GmbH $81.62 08/26/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683643
Principal investigator 1 Novo Nordisk AS $2,500.00 08/22/2025 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4801 No dispute reported 06/30/2026 1213711875
Principal investigator 1 Novo Nordisk AS $1,000.00 08/22/2025 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4801 No dispute reported 06/30/2026 1213726687
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,592.60 08/20/2025 Non-covered Recipient Entity
Diabetes & Glandular Disease Clinic, P.A
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220809947
Principal investigator 1 ABBVIE INC. $34,781.40 08/06/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202503123
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683498
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683637
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,941.20 08/01/2025 Non-covered Recipient Entity
Diabetes & Glandular Disease Clinic, P.A
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220809925
Principal investigator 1 Insulet Corporation $34,427.25 07/29/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLIN
Safety and Efficacy of the Omnipod 5 SmartAdjust 2.0 System Compared to the Omnipod 5 System in Individuals with Type 1 or Type 2 Diabetes No dispute reported 06/30/2026 1206961854
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 07/28/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683641
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,234.48 07/24/2025 Non-covered Recipient Entity
Diabetes & Glandular Disease Clinic, P.A
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220809923
Principal investigator 1 Ionis Pharmaceuticals, Inc. $4,572.00 07/21/2025 Non-covered Recipient Entity
DIABETES & GLANDULAR DISEASE CLINIC PA
IS354CS15 No dispute reported 06/30/2026 1246785482
Principal investigator 1 Novo Nordisk AS $1,867.10 07/21/2025 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4801 No dispute reported 06/30/2026 1213717800
Principal investigator 1 Abbott Laboratories $17.50 07/17/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157854
Principal investigator 1 Abbott Laboratories $6.00 07/17/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157856
Principal investigator 1 Abbott Laboratories $370.00 07/16/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157848
Principal investigator 1 Abbott Laboratories $9,975.00 07/16/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157852
Principal investigator 1 Abbott Laboratories $5.00 07/16/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157858
Principal investigator 1 Abbott Laboratories $22.50 07/16/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157860
Principal investigator 1 Abbott Laboratories $4.99 07/16/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248157862
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,970.90 07/09/2025 Non-covered Recipient Entity
Diabetes & Glandular Disease Clinic, P.A
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220809945
Principal investigator 1 ABBVIE INC. $16,587.45 07/02/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202495719
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683584
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683586
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683588
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683590
Principal investigator 1 Boehringer Ingelheim International GmbH $61.58 07/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683624
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683626
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683629
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683631
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683633
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683635
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,003.10 07/01/2025 Non-covered Recipient Entity
Diabetes & Glandular Disease Clinic, P.A
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220809921
Principal investigator 1 Ionis Pharmaceuticals, Inc. $2,520.00 06/26/2025 Non-covered Recipient Entity
DIABETES & GLANDULAR DISEASE CLINIC PA
IS354CS6 No dispute reported 06/30/2026 1246784788
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,759.40 06/25/2025 Non-covered Recipient Entity
Diabetes & Glandular Disease Clinic, P.A
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220809943
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 06/24/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683572
Principal investigator 1 Boehringer Ingelheim International GmbH $255.50 06/24/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683574
Principal investigator 1 Boehringer Ingelheim International GmbH $12.18 06/24/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683576
Principal investigator 1 Boehringer Ingelheim International GmbH $20.70 06/24/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683578
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,680.80 06/12/2025 Non-covered Recipient Entity
Diabetes & Glandular Disease Clinic, P.A
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220809919
Principal investigator 1 ABBVIE INC. $51,495.75 06/03/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202489201
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683480
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683482
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683484
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683486
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683550
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683552
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683554
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683556
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683558
Principal investigator 1 Novo Nordisk AS $225.00 05/21/2025 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4801 No dispute reported 06/30/2026 1213703240
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $70.00 05/12/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220801034
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $70.00 05/12/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220801048
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,113.10 05/09/2025 Non-covered Recipient Entity
Diabetes & Glandular Disease Clinic, P.A
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220809941
Principal investigator 1 ABBVIE INC. $42,863.85 05/07/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202484061
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,150.60 05/05/2025 Non-covered Recipient Entity
Diabetes & Glandular Disease Clinic, P.A
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220809917
Recipient Corcept Therapeutics $155.90 05/02/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214166581
Recipient Corcept Therapeutics $71.74 05/02/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214166594
Recipient Corcept Therapeutics $76.44 05/02/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214166598
Recipient Corcept Therapeutics $98.62 05/02/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214166603
Recipient Corcept Therapeutics $32.67 05/02/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214166607
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683472
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683474
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683476
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683478
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683540
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683542
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683544
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683546
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683548
Recipient Corcept Therapeutics $501.96 05/01/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214166577
Recipient Corcept Therapeutics $371.77 05/01/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214166586
Recipient Corcept Therapeutics $346.93 05/01/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214166590
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 04/23/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683488
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 04/23/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683490
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 04/23/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683492
Principal investigator 1 Boehringer Ingelheim International GmbH $265.32 04/23/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683494
Principal investigator 1 Boehringer Ingelheim International GmbH $8.70 04/23/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683496
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 04/23/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683560
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 04/23/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683562
Principal investigator 1 Boehringer Ingelheim International GmbH $474.50 04/23/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683564
Principal investigator 1 Boehringer Ingelheim International GmbH $442.20 04/23/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683566
Principal investigator 1 Boehringer Ingelheim International GmbH $10.44 04/23/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683568
Principal investigator 1 Boehringer Ingelheim International GmbH $12.42 04/23/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683570
Principal investigator 1 Novo Nordisk AS $952.20 04/23/2025 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4801 No dispute reported 06/30/2026 1213776342
Principal investigator 1 Abbott Laboratories $149,810.00 04/11/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248137662
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,930.30 04/11/2025 Non-covered Recipient Entity
Diabetes & Glandular Disease Clinic, P.A
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220809915
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,113.10 04/11/2025 Non-covered Recipient Entity
Diabetes & Glandular Disease Clinic, P.A
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220809939
Principal investigator 1 Abbott Laboratories $227,947.00 04/07/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PC
NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System No dispute reported 06/30/2026 1248137664
Principal investigator 1 ABBVIE INC. $10,223.55 04/03/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202471785
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683464
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683466
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683468
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683470
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683530
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683532
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683534
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683536
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683538
Principal investigator 1 Novo Nordisk AS $1,355.40 03/31/2025 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4801 No dispute reported 06/30/2026 1213750671
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,839.60 03/24/2025 Non-covered Recipient Entity
Diabetes & Glandular Disease Clinic, P.A
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220809937
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,597.40 03/19/2025 Non-covered Recipient Entity
Diabetes & Glandular Disease Clinic, P.A
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220809913
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,647.00 03/13/2025 Non-covered Recipient Entity
Diabetes & Glandular Disease Clinic, P.A
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220809911
Principal investigator 1 ABBVIE INC. $31,352.40 03/07/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202459971
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683456
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683458
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683460
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683462
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683518
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683520
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683522
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683524
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683526
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8.00 02/27/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220801042
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8.00 02/27/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220801044
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,714.90 02/21/2025 Non-covered Recipient Entity
Diabetes & Glandular Disease Clinic, P.A
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220809909
Principal investigator 1 Novo Nordisk AS $1,159.20 02/21/2025 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4801 No dispute reported 06/30/2026 1213830002
Principal investigator 1 Medtronic, Inc. $6,120.00 02/14/2025 Non-covered Recipient Entity
Diabetes And Glandular Disease Clinic Pa
CIP336 Fiasp No dispute reported 06/30/2026 1192324303
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2.00 02/12/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220801036
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2.00 02/12/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220801038
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $152.00 02/12/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220801040
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $32.00 02/12/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220801046
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,308.90 02/11/2025 Non-covered Recipient Entity
Diabetes & Glandular Disease Clinic, P.A
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220809907
Principal investigator 1 Medtronic, Inc. $6,850.00 02/07/2025 Non-covered Recipient Entity
Diabetes And Glandular Disease Clinic Pa
CIP335 Lyumjev No dispute reported 06/30/2026 1192324259
Principal investigator 1 Medtronic, Inc. $5,000.00 02/07/2025 Non-covered Recipient Entity
Diabetes And Glandular Disease Clinic Pa
CIP336 Fiasp No dispute reported 06/30/2026 1192324301
Principal investigator 1 ABBVIE INC. $18,999.90 02/06/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202447094
Principal investigator 1 ABBVIE INC. $2,856.60 02/06/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202447155
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683448
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683450
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683452
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683454
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683508
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683510
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683512
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683514
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683516
Principal investigator 1 Eli Lilly and Company $436.00 01/31/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CTR
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1187882842
Principal investigator 1 Novo Nordisk AS $1,449.00 01/31/2025 Non-covered Recipient Entity
HVMG VALLEY INTERNAL MEDICINE
NN9535-4801 No dispute reported 06/30/2026 1213815957
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $150.00 01/30/2025 Non-covered Recipient Entity
Diabetes & Glandular Disease Clinic, P.A
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220809935
Principal investigator 1 Medtronic, Inc. $2,125.00 01/30/2025 Non-covered Recipient Entity
Diabetes And Glandular Disease Clinic Pa
CEP304 HCL Outcomes Study No dispute reported 06/30/2026 1192317394
Principal investigator 1 Amgen Inc. $5,819.58 01/29/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC
A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus No dispute reported 06/30/2026 1246640767
Principal investigator 1 Amgen Inc. $35,781.18 01/27/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC
A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM No dispute reported 06/30/2026 1246640769
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,232.00 01/27/2025 Non-covered Recipient Entity
Diabetes & Glandular Disease Clinic, P.A
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220809933
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $150.00 01/24/2025 Non-covered Recipient Entity
Diabetes & Glandular Disease Clinic, P.A
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220809905
Principal investigator 1 Shionogi Inc $1,200.00 01/24/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC PA
A Phase 2, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Assess the Safety and Efficacy of S-309309 in Obese Adults No dispute reported 06/30/2026 1250719741
Principal investigator 1 Shionogi Inc $1,250.00 01/24/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC PA
A Phase 2, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Assess the Safety and Efficacy of S-309309 in Obese Adults No dispute reported 06/30/2026 1250719744
Principal investigator 1 Shionogi Inc $1,000.00 01/24/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC PA
A Phase 2, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Assess the Safety and Efficacy of S-309309 in Obese Adults No dispute reported 06/30/2026 1250719747
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $696.60 01/22/2025 Non-covered Recipient Entity
Diabetes & Glandular Disease Clinic, P.A
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220809903
Principal investigator 1 Eli Lilly and Company $15,088.00 01/21/2025 Non-covered Recipient Entity
DIABETES & GLANDULAR DISEASE
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1187880785
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,113.10 01/17/2025 Non-covered Recipient Entity
Diabetes & Glandular Disease Clinic, P.A
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220809931
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,500.00 01/08/2025 Non-covered Recipient Entity
DIABETES AND GLANDULAR DISEASE CLINIC, PA
A Phase 2b3 Randomized, Double blind, Placebo controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Participants with Non cirrhotic Non alcoholic Steatohepatitis with Fibrosis No dispute reported 06/30/2026 1185547831
Principal investigator 1 Dexcom, Inc. $2,000.00 01/07/2025 Non-covered Recipient Entity
Diabetes & Glandular Disease Clinic, P.A.
MULTI-SESSION FEASIBILITY STUDY OF THE DEXCOM G7 DELTA CONTINUOUS GLUCOSE MONITORING (CGM) SENSOR IN ADULT AND PEDIATRIC SUBJECTS No dispute reported 06/30/2026 1250961668
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683440
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683442
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683444
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220683446
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683500
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683502
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683504
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683506
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Alamo Specialty Pharmacy-Dgd Pharmacy
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220683528